NTBLQ (Notable Labs) Change In Inventory : $0.00 Mil (TTM As of Jun. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Notable Labs Change In Inventory?

Notable Labs's change in inventory for the quarter that ended in Jun. 2024 was $0.00 Mil. It means Notable Labs's inventory stayed the same from Mar. 2024 to Jun. 2024 .

Notable Labs's change in inventory for the fiscal year that ended in Dec. 2023 was $0.00 Mil. It means Notable Labs's inventory stayed the same from Dec. 2022 to Dec. 2023 .

Notable Labs's Total Inventories for the quarter that ended in Jun. 2024 was $0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Notable Labs's Inventory-to-Revenue for the quarter that ended in Jun. 2024 was 0.00.

Notable Labs Change In Inventory Historical Data

The historical data trend for Notable Labs's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Notable Labs Change In Inventory Chart

Notable Labs Annual Data

Trend

Dec21

Dec22

Dec23

Change In Inventory

Notable Labs Quarterly Data
	Dec21	Dec22	Mar23	Jun23	Dec23	Mar24	Jun24
Change In Inventory	Get a 7-Day Free Trial			-	-	-	-	-

Notable Labs Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Notable Labs (OTCPK:NTBLQ) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Notable Labs's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	0	/	0	*	365 / 4
	=	N/A

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Notable Labs's Inventory Turnover for the quarter that ended in Jun. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	0
	=	N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Notable Labs's Inventory to Revenue for the quarter that ended in Jun. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	0.002
	=	0.00

Notable Labs Change In Inventory Related Terms

Thank you for viewing the detailed overview of Notable Labs's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Notable Labs Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Notable Labs Ltd (OTCPK:NTBLQ) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

N/A

Address

320 Hatch Drive, Foster City, CA, USA, 94404

Website

https://notablelabs.com

Notable Labs Ltd is a clinical-stage platform therapeutics company developing predictive precision medicines for patients with cancer. Through its proprietary Predictive Precision Medicines Platform (PPMP), Notable bio-simulates a cancer treatment to predict whether or not a patient is likely to respond to that specific therapeutic. PPMP is designed to enable Notable to identify and select patients expected to be clinically responsive before the initiation of their treatment and potentially enable fast-track therapeutic development in this patient population.